SANTA CLARA, Calif. & NEW YORK--(BUSINESS WIRE)--Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that John Russell, president and chief executive officer of Cardiva Medical, is scheduled to present a corporate overview at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 4:30 p.m. EST in New York, NY.
About Cardiva Medical, Inc.
Cardiva Medical, Inc. is a privately held medical device company focused on developing and commercializing innovative vascular closure technologies.
The Company’s VASCADE® Vascular Closure System has been PMA approved by the FDA since 2013 and is indicated for vessel closure following 5-7F arterial and venous procedures. VASCADE is the only closure system to demonstrate a statistically significant reduction in access site complications compared to the existing standard of care in a prospective, randomized, controlled clinical trial called RESPECT. The latest product in the Company’s portfolio is VASCADE® MVP Venous Vascular Closure System, which is the first vessel closure technology designed specifically for Electrophysiology procedures – and proven by Electrophysiology physicians in the multi-center, randomized, controlled clinical trial called AMBULATE. VASCADE MVP received PMA approval in late 2018.
Cardiva has won numerous recent awards for clinical, commercial and operational excellence – including the Shingo Bronze Medallion and the MedTech Insight Award – and is on the 2018 Inc 5000 list of the fastest growing private companies in the United States. The Company is headquartered in Santa Clara, California.
For further information, visit our website at www.cardivamedical.com and follow us on Twitter at @CardivaMedical. VASCADE® and Cardiva Catalyst® are registered trademarks of Cardiva Medical®, Inc.